The use of epoetin alfa biosimilar in the anemia management in hemodialysis patients

Abstract. The present study aimed to evaluate the efficacy and safety of EMAVAIL (epoetin alfa) in correction anemia hemodialysis patients.
 Methods. A total 36 patients undergoing regular were enrolled this prospective study. Among 19 (53%) men 17 (47%) women with severe (hemoglobin (Hb) level ≤ 90 g/L). mean patients' age was 48.41±1.82 years, an average dialysis vintage consisted 42.38±10.41 months. All had thrice-weekly sessions, a duration 12.6 ± 0.51 hours per week Kt/V 1.27 0.08. treated biosimilar epoetin alfa intravenously three times adjustable doses. follow-up period 56 days.
 Results. At entry, Hb 81.7±0,93 g/L. In days treatment, concentration increased 109.17±1.75 Eventually, 32 (89%) achieved target (110 g/L); 6 (17%) adverse events (mild hypertension). There no serious events.
 Conclusions. is effective safe for management patients.